Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs28934575
rs28934575
T 0.700 GeneticVariation CLINVAR

dbSNP: rs1057519847
rs1057519847
0.100 GeneticVariation BEFREE EGFR L858R was more frequently harbored in the MP+ adenocarcinoma patients than in the MP- adenocarcinoma patients. 31732945

2020

dbSNP: rs1057519848
rs1057519848
0.100 GeneticVariation BEFREE EGFR L858R was more frequently harbored in the MP+ adenocarcinoma patients than in the MP- adenocarcinoma patients. 31732945

2020

dbSNP: rs121434568
rs121434568
0.100 GeneticVariation BEFREE EGFR L858R was more frequently harbored in the MP+ adenocarcinoma patients than in the MP- adenocarcinoma patients. 31732945

2020

dbSNP: rs1057519847
rs1057519847
0.100 GeneticVariation BEFREE The patient was a 67-year-old male with a diagnosis of metastatic pulmonary adenocarcinoma with an L858R mutation on exon 21. 31371992

2019

dbSNP: rs1057519848
rs1057519848
0.100 GeneticVariation BEFREE The patient was a 67-year-old male with a diagnosis of metastatic pulmonary adenocarcinoma with an L858R mutation on exon 21. 31371992

2019

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Moreover, a 47-year-old female with a recurrent adenocarcinoma and a BRAF V600E mutation exhibited tumor regression after a fourth line therapy with dabrafenib and trametinib, targeting agents against BRAF mutations. 31440061

2019

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Lung ADCA harbouring BRAF mutations are commonly non-V600E. 30591192

2019

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE BRAF mutation (V600E) was seen in one de novo-type case and two CIA-type cases, but none of these cases had MMR protein loss. 31282116

2019

dbSNP: rs121434568
rs121434568
0.100 GeneticVariation BEFREE The patient was a 67-year-old male with a diagnosis of metastatic pulmonary adenocarcinoma with an L858R mutation on exon 21. 31371992

2019

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE We studied the prevalence of T790M mutation among pulmonary adenocarcinoma patients in Lebanese patients based on liquid biopsy testing the circulating tumor DNA (ctDNA). 31147859

2019

dbSNP: rs121434569
rs121434569
0.100 GeneticVariation BEFREE After 12 mo of treatment with icotinib, ovarian biopsy showed adenocarcinoma with CDX2(-), TTF-1(+++), PAX8(-), CK-7(+++), CK-20(++), and Ki67(15%+), accompanied with EGFR 19-del mutation and T790M mutation. 31363481

2019

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE Lung ADCA harbouring BRAF mutations are commonly non-V600E. 30591192

2019

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE Moreover, a 47-year-old female with a recurrent adenocarcinoma and a BRAF V600E mutation exhibited tumor regression after a fourth line therapy with dabrafenib and trametinib, targeting agents against BRAF mutations. 31440061

2019

dbSNP: rs121913377
rs121913377
0.100 GeneticVariation BEFREE BRAF mutation (V600E) was seen in one de novo-type case and two CIA-type cases, but none of these cases had MMR protein loss. 31282116

2019

dbSNP: rs1057519847
rs1057519847
0.100 GeneticVariation BEFREE Inclusion criteria were histologic diagnosis of benign nodule (control) and stage I or II adenocarcinoma harboring either p.L858R or ex</span>on19 delEGFR mutations. 30309763

2018

dbSNP: rs1057519847
rs1057519847
0.100 GeneticVariation BEFREE This case represents the first evidence that 1) bevacizumab combined with osimertinib can significantly relieve tumor growth and respiratory symptoms in non-small-cell lung cancer patients with osimertinib resistance and 2) the clinical use of osimertinib, bevacizumab, and brigatinib is effective as combination therapy for pulmonary adenocarcinoma in the presence of triple EGFR mutations of L858R, T790M, and <i>cis</i>-C797S. 30233215

2018

dbSNP: rs1057519847
rs1057519847
0.100 GeneticVariation BEFREE We enrolled consecutive patients with operable adenocarcinoma which harbored 19del or L858R to investigate the clinicopathologic characteristics and prognostic outcomes. 29026990

2018

dbSNP: rs1057519847
rs1057519847
0.100 GeneticVariation BEFREE A 62-year-old Asian male never smoker who presented with stage IV EGFR L858R-positive adenocarcinoma developed EGFR T790 M mutation after 14 months of treatment with erlotinib combined with thoracic radiotherapy as first-line therapy. 30400855

2018

dbSNP: rs1057519848
rs1057519848
0.100 GeneticVariation BEFREE Inclusion criteria were histologic diagnosis of benign nodule (control) and stage I or II adenocarcinoma harboring either p.L858R or ex</span>on19 delEGFR mutations. 30309763

2018

dbSNP: rs1057519848
rs1057519848
0.100 GeneticVariation BEFREE We enrolled consecutive patients with operable adenocarcinoma which harbored 19del or L858R to investigate the clinicopathologic characteristics and prognostic outcomes. 29026990

2018

dbSNP: rs1057519848
rs1057519848
0.100 GeneticVariation BEFREE This case represents the first evidence that 1) bevacizumab combined with osimertinib can significantly relieve tumor growth and respiratory symptoms in non-small-cell lung cancer patients with osimertinib resistance and 2) the clinical use of osimertinib, bevacizumab, and brigatinib is effective as combination therapy for pulmonary adenocarcinoma in the presence of triple EGFR mutations of L858R, T790M, and <i>cis</i>-C797S. 30233215

2018

dbSNP: rs1057519848
rs1057519848
0.100 GeneticVariation BEFREE A 62-year-old Asian male never smoker who presented with stage IV EGFR L858R-positive adenocarcinoma developed EGFR T790 M mutation after 14 months of treatment with erlotinib combined with thoracic radiotherapy as first-line therapy. 30400855

2018

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE A case of a primary lung cancer comprised of adenocarcinoma and atypical carcinoid tumor with both components harboring BRAF p.V600E mutation. 29248665

2018

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Patients (<i>n</i> = 59) from 24 centres were included: 57.6% men; mean age: 64.5 ± 14.5 years; 82% with a performance status of 0-1 at diagnosis; smoking status: 40.3% current, 32.6% former; 93% with adenocarcinoma histology; 75% stage iv; 78% with V600E mutations; 2 with <i>EGFR</i> and 2 with <i>ALK</i> co-mutations. 30464690

2018